

DRUG QUANTITY MANAGEMENT POLICY – PER RX

POLICY: Oncology – Qinlock Drug Quantity Management Policy – Per Rx

- Qinlock® (ripretinib tablets – Deciphera)

REVIEW DATE: 05/11/2022

OVERVIEW

Qinlock, a kinase inhibitor, is indicated for the treatment of adult patients with advanced **gastrointestinal stromal tumor** who have received prior treatment with three or more kinase inhibitors, including imatinib.¹

Dosing

The recommended dose of Qinlock is 150 mg once daily (QD) with or without food until disease progression or unacceptable toxicity.¹ Tablets must be swallowed whole. If vomiting occurs after Qinlock, the patient should not take an additional dose, but continue with the next dose as scheduled. A dose reduction to 100 mg QD may be needed to manage adverse events. Patients taking Qinlock should avoid coadministration with moderate or severe cytochrome P450 (CYP)3A inducers. However, if coadministration with a moderate CYP3A inducer cannot be avoided, increase the dosing frequency of Qinlock to 150 mg twice daily. After the inducer has been discontinued for at least 14 days, the prior dose of Qinlock may be resumed.

Availability

Qinlock is available as 50 mg tablets supplied in bottles of 90 tablets.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Qinlock. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Dosage Form	Maximum Quantity per Rx
Qinlock® (ripretinib tablets)	50 mg tablets	90 tablets*

* This is a sufficient quantity for a 30-day supply of Qinlock dosed at 150 mg once daily.

CRITERIA

1. If the patient is taking a moderate cytochrome P450 (CYP)3A inducer, approve 180 tablets per dispensing.

Note: Moderate CYP3A inducers include, but are not limited to, bosentan, efavirenz, etravirine, phenobarbital, and primidone.

REFERENCES

1. Qinlock® tablets [prescribing information]. Waltham, MA: Deciphera; June 2021.

05/11/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

